Show simple item record

dc.contributor.authorPatarroyo, Manuel-Alfonso
dc.contributor.authorPatarroyo, Manuel-Elkin
dc.contributor.authorPabón, Laura
dc.contributor.authorAlba, Martha patricia
dc.contributor.authorBermudez, Adriana
dc.contributor.authorRugeles, María Teresa
dc.contributor.authorDiaz-Arevalo, Diana
dc.contributor.authorZapata, Wildeman
dc.contributor.authorZapata, María Isabel
dc.contributor.authorReyes, César
dc.contributor.authorSuarez, Carlos F.
dc.contributor.authorAgudelo, William
dc.date.accessioned2022-08-10T18:46:55Z
dc.date.available2022-08-10T18:46:55Z
dc.date.issued2022
dc.identifier.citationPatarroyo, M. A., Patarroyo, M. E., Pabón, L., Alba, M. P., Bermudez, A., Rugeles, M. T., . . . Avendaño, C. (2022). SM-COLSARSPROT: Highly immunogenic supramutational synthetic peptides covering the World’s population. Frontiers in Immunology, 13 doi:10.3389/fimmu.2022.859905spa
dc.identifier.issn1664-3224spa
dc.identifier.urihttps://repository.udca.edu.co/handle/11158/4811
dc.description.abstractFifty ~20–amino acid (aa)–long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus’ main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPIIL) formation, replacing β-branched, aromatic aa, short-chain backbone H-bond-forming residues, π-π interactions (n→π* and π-CH), aa interaction with π systems, and molecular fragments able to interact with them, disrupting PPIIL propensity formation. All these modified structures had PPIIL formation propensity to enable target peptide interaction with human leukocyte antigen-DRβ1* (HLA-DRβ1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DRβ1* molecules), predicted to cover 77.5% to 83.1% of the world’s population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development.eng
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.eseng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://www.frontiersin.org/articles/10.3389/fimmu.2022.859905/fullspa
dc.titleSM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Populationeng
dc.typeArtículo de revistaspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)spa
dc.description.notesIncluye referencias bibliográficas.spa
dc.identifier.doi10.3389/fimmu.2022.859905
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.subject.agrovocPéptidos sintéticos
dc.subject.agrovocCoronavirus del síndrome respiratorio agudo grave 2
dc.subject.agrovocVariantes
dc.relation.indexedN/Aspa
dc.relation.citationedition(May., 2022) Artículo Número 859905spa
dc.relation.citationendpage23spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume13spa
dc.relation.ispartofjournalFrontiers in Immunologyspa
dc.type.contentTextspa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.es
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.es